Document Type
Article
Publication Date
6-10-2022
Abstract
Previously undescribed molecular mechanisms of resistance will emerge with the increased use of cyclin-dependent kinase 4/6 inhibitors in clinical settings. To identify genomic aberrations in circulating tumor DNA associated with treatment resistance in palbociclib-treated metastatic breast cancer (MBC) patients, we collected 35 pre- and post-treatment blood samples from 16 patients with estrogen receptor-positive (ER
Recommended Citation
Abu-Khalaf, Maysa; Wang, Chun; Zhang, Zhenchao; Luo, Rui; Chong, Weelic; Silver, Daniel P.; Fellin, Frederick; Jaslow, Rebecca J.; Lopez, MD, MPH, MACP, Ana Maria; Cescon, Terrence; Jiang, MD, PhD, Wei; Myers, PhD, DSW, Ronald E.; Wei, Qiang; Li, Bingshan; Cristofanilli, Massimo; and Yang, Hushan, "Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism." (2022). Department of Medical Oncology Faculty Papers. Paper 196.
https://jdc.jefferson.edu/medoncfp/196
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
35740538
Language
English
Comments
This is the final published version of the article from the journal Cancers, 2022, 14, 2872.
The article can also be accessed on the journal's website: https://doi.org/10.3390/ cancers14122872
Copyright. The Authors.
Publication made possible in part by support from the Jefferson Open Access Fund